ASTRO 2022 abstracts featured notable research findings for use of radiotherapy in diseases such as early-stage breast cancer, orbital indolent B-cell lymphoma, and locally advanced cervical cancer.
Allograft Renal Cell Carcinoma From the Donor: Rare, but Possible
An unusual case of donor-derived renal cell carcinoma in a kidney allograft should serve to raise awareness of the possibility, but not to discourage people from kidney donation.
Infiltrative Renal Masses: More Common Than Previously Thought and Often Unrecognized
It is well established that infiltrative renal masses (IRMs) are mostly malignant and aggressive. Yet, until recently, the standard practice in radiology hasn’t been to routinely assess or document IRMs. To better understand the prevalence and significance of IRMs, researchers in the Glickman Urological & Kidney Institute led a new and revealing investigation.
Genetic Models for Renal Cell Carcinoma Risk Stratification: Current Status and Future Prospects
These three genetic models could help refine recurrence risk and guide treatment decisions for patients with renal cell carcinoma.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
New Renal Cancer Therapy Effective in Higher Risk Groups
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.
Examining Operative Experience with Radical Nephrectomy and IVC Thrombectomy
A case series reviewing Cleveland Clinic’s nearly 30 years of surgical experience with radical nephrectomy and inferior vena cava thrombectomy provides a wealth of information regarding thrombus level, operative technique, outcomes and complications.
KEYNOTE-426: Pembrolizumab + Axitinib or Sunitinib Alone for Advanced Renal Cell Carcinoma?
Staggering results in this phase 3 trial point to the future of care for advanced renal cell carcinoma.
Multigene Assay Holds Prognostic Promise for Renal Cell Carcinoma
This study confirms the assay’s validity and provides the required level 1B evidence needed for inclusion in treatment guidelines.
Targeted Therapies + SRS Combo Prolongs Survival in Patients with Renal Cell Carcinoma Brain Metastases
Research shows targeted therapies along with stereotactic radiosurgery increase survival in patients with metastatic renal cell carcinoma. But what about for patients with brain metastases?
Sunitinib Treatment Breaks Feasible for Metastatic Renal Cell Carcinoma
Intermittent sunitinib dosing does not compromise clinical efficacy and is feasible in patients with previously untreated metastatic renal cell carcinoma, according to a phase 2 Cleveland Clinic study.